Rosuvastatin preserves renal function and lowers cystatin C in HIV-Infected subjects on antiretroviral therapy: The SATURN-HIV Trial

Clinical Infectious Diseases

Volumn 59, Issue 8, 2014, Pages 1148-1156

  Longenecker, Chris T ^a,b   Hileman, Corrilynn O ^a,c   Funderburg, Nicholas T ^d   McComsey, Grace A ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^c METROHEALTH MEDICAL CENTER   (United States)

^d OHIO STATE UNIVERSITY   (United States)

Author keywords

Cystatin C; HIV; Inflammation; Kidney; Statin

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; CREATININE; CYSTATIN C; DIDANOSINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE PLUS ZIDOVUDINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MARAVIROC; PLACEBO; PROTEINASE INHIBITOR; ROSUVASTATIN; TENOFOVIR; BIOLOGICAL MARKER; CST3 PROTEIN, HUMAN; FLUOROBENZENE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

ADULT; AFRICAN AMERICAN; ARTERIAL WALL THICKNESS; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DOUBLE BLIND PROCEDURE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENDOTHELIUM CELL; EPICARDIAL FAT; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOREACTIVITY; INFLAMMATION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE ACTIVATION; VASCULAR DISEASE; AIDS-ASSOCIATED NEPHROPATHY; HIV INFECTIONS; KIDNEY; KIDNEY FUNCTION TEST; PATHOLOGY; PHYSIOLOGY; TREATMENT OUTCOME;

ADULT; AIDS-ASSOCIATED NEPHROPATHY; ANTI-RETROVIRAL AGENTS; BIOMARKERS; CYSTATIN C; FEMALE; FLUOROBENZENES; HIV INFECTIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; KIDNEY; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; PLACEBOS; PYRIMIDINES; ROSUVASTATIN CALCIUM; SULFONAMIDES; TREATMENT OUTCOME;

EID: 84986260208     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu523     Document Type: Article

References (40)

1. Choi AI, Li Y, Deeks SG, Grunfeld C, Volberding PA, Shlipak MG. Association between kidney function and albuminuria with cardiovascular events in HIV-infected persons. Circulation 2010; 121:651-8.
2. Choi AI, Rodriguez RA, Bacchetti P, Bertenthal D, Volberding PA, O'Hare AM. The impact of HIV on chronic kidney disease outcomes. Kidney Int 2007; 72:1380-7.
3. Longenecker CT, Scherzer R, Bacchetti P, Lewis CE, Grunfeld C, Shlipak MG. HIV viremia and changes in kidney function. AIDS 2009; 23:1089-96.
4. Mocroft A, Kirk O, Reiss P, et al. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS 2010; 24:1667-78.
5. Gagneux-Brunon A, Delanaye P, Maillard N, et al. Performance of creatinine and cystatin C-based glomerular filtration rate estimating equations in a European HIV-positive cohort. AIDS 2013; 27:1573-81.
6. Inker LA, Wyatt C, Creamer R, et al. Performance of creatinine and cystatin C GFR estimating equations in an HIV-positive population on antiretrovirals. J Acquir Immune Defic Syndr 2012; 61:302-9.
7. Bhasin B, Lau B, Atta MG, et al. HIV viremia and T-cell activation differentially affect the performance of glomerular filtration rate equations based on creatinine and cystatin C. PLoS One 2013; 8:e82028.
8. Krane V, Wanner C. Statins, inflammation and kidney disease. Nat Rev Nephrol 2011; 7:385-97.
9. Hunt PW. HIV and inflammation: mechanisms and consequences. Curr HIV/AIDS Rep 2012; 9:139-47.
10. Lucas G, Cozzi-Lepri A, Wyatt C, et al. Glomerular filtration rate estimated using creatinine, cystatin C or both markers and the risk of clinical events in HIV-infected individuals. HIV Med 2013; 15:116-23.
11. Goicoechea M, de Vinuesa SG, Lahera V, et al. Effects of atorvastatin on inflammatory and fibrinolytic parameters in patients with chronic kidney disease. J Am Soc Nephrol 2006; 17:S231-5.
12. Savarese G, Musella F, Volpe M, Paneni F, Perrone-Filardi P. Effects of atorvastatin and rosuvastatin on renal function: a meta-Analysis. Int J Cardiol 2013; 167:2482-9.
13. Eckard AR, Jiang Y, Debanne SM, Funderburg NT, McComsey GA. The effect of 24 weeks of statin therapy on systemic and vascular inflammation in HIV-infected subjects on antiretroviral therapy. J Infect Dis 2014; 209:1156-64.
14. Aslangul E, Fellahi S, Assoumou LK, Bastard JP, Capeau J, Costagliola D. High-sensitivity C-reactive protein levels fall during statin therapy in HIV-infected patients receiving ritonavir-boosted protease inhibitors. AIDS 2011; 25:1128-31.
15. Funderburg NT, Jiang Y, Debanne SM, et al. Rosuvastatin treatment reduces markers of monocyte activation in HIV infected subjects on antiretroviral therapy. Clin Infect Dis 2014; 58:588-95.
16. Fichtenbaum CJ, Yeh TM, Evans SR, Aberg JA. Treatment with pravastatin and fenofibrate improves atherogenic lipid profiles but not inflammatory markers in ACTG 5087. J Clin Lipidol 2010; 4:279-87.
17. Ganesan A, Crum-Cianflone N, Higgins J, et al. High dose atorvastatin decreases cellular markers of immune activation without affecting HIV-1 RNA levels: results of a double-blind randomized placebo controlled clinical trial. J Infect Dis 2011; 203:756-64.
18. Baker JV, Huppler Hullsiek K, Prosser R, et al. Angiotensin converting enzyme inhibitor and HMG-CoA reductase inhibitor as adjunct treatment for persons with HIV infection: a feasibility randomized trial. PLoS One 2012; 7:e46894.
19. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359:2195-207.
20. McComsey GA, Kitch D, Sax PE, et al. Peripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG Study A5224s. Clin Infect Dis 2011; 53:185-96.
21. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28:412-9.
22. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97:1837-47.
23. Inker LA, Schmid CH, Tighiouart H, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med 2012; 367:20-9.
24. Longenecker CT, Jiang Y, Orringer CE, et al. Soluble CD14 is independently associated with coronary calcification and extent of subclinical vascular disease in treated HIV infection. AIDS 2014; 28:969-77.
25. Longenecker CT, Jiang Y, Yun CH, et al. Perivascular fat, inflammation, and cardiovascular risk in HIV-infected patients on antiretroviral therapy. Int J Cardiol 2013; 168:4039-45.
26. Kaplan RC, Sinclair E, Landay AL, et al. T cell activation predicts carotid artery stiffness among HIV-infected women. Atherosclerosis 2011; 217:207-13.
27. Seaberg EC, Benning L, Sharrett AR, et al. Association between human immunodeficiency virus infection and stiffness of the common carotid artery. Stroke 2010; 41:2163-70.
28. Longenecker C, Funderburg N, Jiang Y, et al. Markers of inflammation and CD8 T-cell activation, but not monocyte activation, are associated with subclinical carotid artery disease in HIV-infected individuals. HIV Med 2013; 14:385-90.
29. Funderburg NT, Zidar DA, Shive C, et al. Shared monocyte subset phenotypes in HIV-1 infection and in uninfected subjects with acute coronary syndromes. Blood 2012; 120:4599-608.
30. Ridker PM, MacFadyen J, Cressman M, Glynn RJ. Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-An Intervention Trial Evaluating Rosuvastatin) trial. J Am Coll Cardiol 2010; 55:1266-73.
31. Strippoli GF, Navaneethan SD, Johnson DW, et al. Effects of statins in patients with chronic kidney disease: meta-Analysis and meta-regression of randomised controlled trials. BMJ 2008; 336:645-51.
32. Tonelli M, Isles C, Craven T, et al. Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation 2005; 112:171-8.
33. Rutter MK, Prais HR, Charlton-Menys V, et al. Protection against nephropathy in diabetes with atorvastatin (PANDA): a randomized double-blind placebo-controlled trial of high-vs. low-dose atorvastatin( 1). Diabet Med 2011; 28:100-8.
34. Cooper RD,Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M. Systematic review and meta-Analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis 2010; 51:496-505.
35. Tonelli M, Sacks F, Pfeffer M, et al. Biomarkers of inflammation and progression of chronic kidney disease. Kidney Int 2005; 68:237-45.
36. Keller C, Katz R, Cushman M, Fried LF, Shlipak M. Association of kidney function with inflammatory and procoagulant markers in a diverse cohort: a cross-sectional analysis from the Multi-Ethnic Study of Atherosclerosis (MESA). BMC Nephrol 2008; 9:9.
37. Dubin R, Shlipak M, Li Y, et al. Racial differences in the association of pentraxin-3 with kidney dysfunction: the Multi-Ethnic Study of Atherosclerosis. Nephrol Dial Transplant 2011; 26:1903-8.
38. Serrano-Villar S, Estrada V, Gomez-Garre D, et al. Incipient renal impairment as a predictor of subclinical atherosclerosis in HIV-infected patients. J Acquir Immune Defic Syndr 2012; 59:141-8.
39. Choi A, Scherzer R, Bacchetti P, et al. Cystatin C, albuminuria, and 5-year all-cause mortality in HIV-infected persons. Am J Kidney Dis 2010; 56:872-82.
40. Jotwani V, Scherzer R, Choi A, et al. Reduced kidney function and preclinical atherosclerosis in HIV-infected individuals: the study of fat redistribution and metabolic change in HIV infection (FRAM). Am J Nephrol 2011; 33:453-60.